Enanta Pharmaceuticals Inc (NASDAQ:ENTA) – Analysts at Oppenheimer decreased their Q2 2020 earnings per share estimates for Enanta Pharmaceuticals in a research report issued on Monday, February 10th. Oppenheimer analyst J. Olson now forecasts that the biotechnology company will post earnings per share of ($0.83) for the quarter, down from their prior forecast of ($0.71). Oppenheimer also issued estimates for Enanta Pharmaceuticals’ Q3 2020 earnings at ($0.81) EPS, Q4 2020 earnings at ($0.61) EPS, FY2020 earnings at ($1.57) EPS, FY2021 earnings at ($3.84) EPS, FY2022 earnings at ($5.90) EPS, FY2023 earnings at ($6.71) EPS and FY2024 earnings at ($5.58) EPS.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Thursday, February 6th. The biotechnology company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.06. The firm had revenue of $52.57 million for the quarter, compared to analysts’ expectations of $58.75 million. Enanta Pharmaceuticals had a return on equity of 7.39% and a net margin of 18.00%. The company’s quarterly revenue was down 24.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.25 earnings per share.
Other research analysts have also recently issued research reports about the company. JMP Securities cut Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Friday, November 22nd. ValuEngine upgraded Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. BidaskClub upgraded Enanta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, February 6th. Finally, Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Enanta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $96.50.
ENTA opened at $51.89 on Thursday. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of 32.03 and a beta of 0.85. The stock’s 50 day moving average price is $57.20 and its 200-day moving average price is $63.50. Enanta Pharmaceuticals has a one year low of $51.00 and a one year high of $106.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 17.77 and a current ratio of 23.02.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its stake in Enanta Pharmaceuticals by 19.5% during the first quarter. FMR LLC now owns 240,195 shares of the biotechnology company’s stock valued at $22,944,000 after buying an additional 39,200 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of Enanta Pharmaceuticals by 11.9% in the 1st quarter. First Trust Advisors LP now owns 25,234 shares of the biotechnology company’s stock worth $2,410,000 after purchasing an additional 2,681 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Enanta Pharmaceuticals by 42.6% in the 2nd quarter. Bank of America Corp DE now owns 41,785 shares of the biotechnology company’s stock worth $3,525,000 after purchasing an additional 12,483 shares in the last quarter. Morgan Stanley increased its holdings in shares of Enanta Pharmaceuticals by 40.4% in the 2nd quarter. Morgan Stanley now owns 108,964 shares of the biotechnology company’s stock worth $9,194,000 after purchasing an additional 31,335 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Enanta Pharmaceuticals by 1.5% in the 2nd quarter. BlackRock Inc. now owns 2,592,357 shares of the biotechnology company’s stock worth $218,743,000 after purchasing an additional 37,417 shares in the last quarter. 89.32% of the stock is currently owned by hedge funds and other institutional investors.
In related news, CFO Paul J. Mellett sold 10,000 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $60.88, for a total value of $608,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.93% of the stock is owned by corporate insiders.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Featured Article: How can you know how many shares are floating?
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.